CA2951816A1 - Systemic in vivo delivery of oligonucleotides - Google Patents

Systemic in vivo delivery of oligonucleotides Download PDF

Info

Publication number
CA2951816A1
CA2951816A1 CA2951816A CA2951816A CA2951816A1 CA 2951816 A1 CA2951816 A1 CA 2951816A1 CA 2951816 A CA2951816 A CA 2951816A CA 2951816 A CA2951816 A CA 2951816A CA 2951816 A1 CA2951816 A1 CA 2951816A1
Authority
CA
Canada
Prior art keywords
oligonucleotide
hes
nucleic acid
disease
mirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2951816A
Other languages
English (en)
French (fr)
Inventor
Beverly Packard
Akira Komoriya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncoimmunin Inc
Original Assignee
Oncoimmunin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmunin Inc filed Critical Oncoimmunin Inc
Publication of CA2951816A1 publication Critical patent/CA2951816A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
CA2951816A 2013-06-12 2014-06-12 Systemic in vivo delivery of oligonucleotides Abandoned CA2951816A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361834383P 2013-06-12 2013-06-12
US61/834,383 2013-06-12
PCT/US2014/042202 WO2014201306A1 (en) 2013-06-12 2014-06-12 Systemic in vivo delivery of oligonucleotides

Publications (1)

Publication Number Publication Date
CA2951816A1 true CA2951816A1 (en) 2014-12-18

Family

ID=52022784

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2951816A Abandoned CA2951816A1 (en) 2013-06-12 2014-06-12 Systemic in vivo delivery of oligonucleotides

Country Status (5)

Country Link
US (3) US20160367587A1 (enExample)
EP (1) EP3007705A4 (enExample)
JP (2) JP7011389B2 (enExample)
CA (1) CA2951816A1 (enExample)
WO (1) WO2014201306A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016161388A1 (en) 2015-04-03 2016-10-06 University Of Massachusetts Fully stabilized asymmetric sirna
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
JP2019505498A (ja) 2015-12-16 2019-02-28 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害
EP4678748A2 (en) 2015-12-21 2026-01-14 Novartis AG Compositions and methods for decreasing tau expression
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
CA3064590A1 (en) 2017-06-23 2018-12-27 University Of Massachusetts Two-tailed self-delivering sirna and related methods
US20210371855A1 (en) * 2018-06-15 2021-12-02 Ideaya Biosciences, Inc. Methods of inhibiting proliferative cells
WO2020033899A1 (en) 2018-08-10 2020-02-13 University Of Massachusetts Modified oligonucleotides targeting snps
JP7627042B2 (ja) 2018-08-23 2025-02-05 ユニバーシティー オブ マサチューセッツ Ｏ－メチルリッチ完全安定化オリゴヌクレオチド
WO2020150636A1 (en) 2019-01-18 2020-07-23 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
US11820985B2 (en) 2019-03-26 2023-11-21 University Of Massachusetts Modified oligonucleotides with increased stability
WO2020206115A2 (en) * 2019-04-03 2020-10-08 Bristol-Myers Squibb Company Angptl2 antisense oligonucleotides and uses thereof
CA3149835A1 (en) 2019-08-09 2021-02-18 University Of Massachusetts Chemically modified oligonucleotides targeting snps
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
WO2021132648A1 (ja) * 2019-12-27 2021-07-01 ルクサナバイオテク株式会社 Ｒｅｃｑｌの発現を阻害するアンチセンスオリゴヌクレオチド及びその用途
US20230201361A1 (en) * 2020-01-11 2023-06-29 Oncolmmunin, Inc. Targeted and localized in vivo delivery of oligonucleotides
WO2021183624A1 (en) * 2020-03-10 2021-09-16 University Of Central Florida Research Foundation, Inc. Delivery of gene expression modulating agents for therapy against cancer and viral infection
US12146136B2 (en) 2020-03-26 2024-11-19 University Of Massachusetts Synthesis of modified oligonucleotides with increased stability
EP4157289A4 (en) 2020-05-26 2024-06-26 University Of Massachusetts Synthetic oligonucleotides having regions of block and cluster modifications
US20230065782A1 (en) * 2021-07-14 2023-03-02 Oncoimmunin, Inc. Targeted and localized in vivo delivery of oligonucleotides
WO2025171411A1 (en) 2024-02-09 2025-08-14 Herophilus, Inc. Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
WO2025227100A2 (en) * 2024-04-26 2025-10-30 Purdue Research Foundation Targeted delivery of therapeutic agent to retinal pigment epithelium in treatment of ocular diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893868B2 (en) * 1997-02-20 2005-05-17 Onco Immunin, Inc. Homo-doubly labeled compositions for the detection of enzyme activity in biological samples
US6133032A (en) * 1999-09-09 2000-10-17 Isis Pharmaceutical Inc. Antisense modulation of PI3 kinase p110 beta expression
DK1337547T3 (da) * 2000-11-03 2014-06-10 Isis Pharmaceuticals Inc Nuklease-baseret fremgangsmåde til detektion og kvantificering af oligonukleotider
WO2003020739A2 (en) * 2001-09-04 2003-03-13 Exiqon A/S Novel lna compositions and uses thereof
SI2264172T1 (sl) * 2002-04-05 2017-12-29 Roche Innovation Center Copenhagen A/S Oligomerne spojine za modulacijo izražanja HIF-1alfa
AU2003276666A1 (en) * 2002-06-12 2003-12-31 Ambion, Inc. Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20050142581A1 (en) * 2003-09-04 2005-06-30 Griffey Richard H. Microrna as ligands and target molecules
WO2005113571A2 (en) * 2004-05-13 2005-12-01 The University Of North Carolina At Chapel Hill Methods for the delivery of oligomeric compounds
WO2008134593A1 (en) * 2007-04-25 2008-11-06 President And Fellows Of Harvard College Molecular circuits
KR20100051795A (ko) * 2007-06-22 2010-05-18 키진 엔.브이. 향상된 변형 올리고뉴클레오티드를 이용한 표적화 뉴클레오티드 교환
WO2009045536A2 (en) * 2007-10-05 2009-04-09 The University Of North Carolina At Chapel Hill Receptor targeted oligonucleotides
US8911948B2 (en) * 2008-04-30 2014-12-16 Integrated Dna Technologies, Inc. RNase H-based assays utilizing modified RNA monomers
WO2010071852A2 (en) * 2008-12-19 2010-06-24 University Of Florida Research Foundation, Inc. Oligonucleotide micelles
JP5685267B2 (ja) * 2009-12-09 2015-03-18 日東電工株式会社 Ｈｓｐ４７発現の調節
WO2013090457A2 (en) * 2011-12-12 2013-06-20 Oncoimmunin Inc. In vivo delivery of oligonucleotides

Also Published As

Publication number Publication date
JP7011389B2 (ja) 2022-01-26
US20190183918A1 (en) 2019-06-20
EP3007705A1 (en) 2016-04-20
EP3007705A4 (en) 2017-02-15
WO2014201306A1 (en) 2014-12-18
US20160367587A1 (en) 2016-12-22
US20220033815A1 (en) 2022-02-03
JP2019135259A (ja) 2019-08-15
JP2016521753A (ja) 2016-07-25

Similar Documents

Publication Publication Date Title
US20240401040A1 (en) In vivo delivery of oligonucleotides
US20220033815A1 (en) Systemic in vivo delivery of oligonucleotides
US8404659B2 (en) Pharmaceutical compositions for treatment of MicroRNA related diseases
CA2921457A1 (en) Heterochromatin forming non-coding rnas
JP2026066248A (ja) オリゴヌクレオチドの標的化及び局所インビボ送達
CA3171986A1 (en) Oligonucleotides
US11072795B2 (en) Antisense oligonucleotides
CA3016592A1 (en) Targeting microrna for cancer treatment
US20230065782A1 (en) Targeted and localized in vivo delivery of oligonucleotides
JP7208911B2 (ja) 核酸分子発現の調節
EP2978847B1 (en) Hammerhead ribozymes targeting mir-21
WO2022263931A2 (en) Compositions and methods for treating cancer

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200831